Tanios Bekaii-Saab, MD, FACP

Section Chief, Gastrointestinal Oncology

The Ohio State University Comprehensive Cancer Center

Eileen M. O'Reilly, MD

Associate Director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research

Memorial Sloan Kettering Cancer Center

Eileen M. O’Reilly, MD, is the associate director for clinical research for the David M. Rubenstein Center for Pancreatic Cancer Research, is an attending physician and member at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, and is professor of medicine at Weill Medical College of Cornell University.

Dr O’Reilly received her medical degree at Trinity College (Dublin University) in Ireland, where she was born, and completed her residency training in Ireland and fellowship training at MSKCC. Pancreatic and hepatobiliary malignancies are the major focus of her research and clinical activities. Her research initiatives include integration of molecular and genetic-based therapies for the treatment of pancreatic cancer, along with development of adjuvant and neoadjuvant therapies and identification of biomarkers that may be used to select therapy.

Dr O’Reilly teaches and mentors oncology fellows (national and international), junior faculty, residents and house staff, and has numerous teaching and other awards. She is the principal investigator of multiple phase I, II and III trials in pancreatic cancer, and has authored/co-authored multiple articles, editorials, and book chapters. Dr O’Reilly’s other institutional responsibilities include associate chairpersonship of MSKCC’s Institutional Review & Privacy Board (IRB), membership of the Research Council, and chair of the Continuing Medical Education (CME) committee. Nationally Dr O’Reilly is the chair of the NCI Pancreas Task Force, co-chair of the Alliance GI committee, and serves on the scientific advisory board of the Pancreatic Cancer Action Network, NCCN pancreas panel, board of the National Pancreas Foundation, and the ASCO IMT committee.

Determining Optimal Treatments for Patients with Metastatic Pancreatic Cancer (MPC)

Emerging Targets, Biomarkers, and Imaging Techniques in the Treatment of Patients with Metastatic Pancreatic Cancer (MPC)

Wasif Saif, MD

Professor of Medicine; Director, GI Oncology Program

Tufts University School of Medicine

Wasif M. Saif, MD, is professor of medicine, director of the Gastrointestinal Oncology Program, and program leader for Experimental Therapeutics, Department of Medicine, at Tufts University School of Medicine and Tufts Medical Center in Boston, Massachusetts. Dr Saif specializes in caring for patients with gastrointestinal malignancies; in particular, pancreatic and colorectal cancers. Over the last two decades, his research efforts have focused on the developing novel agents and treatment approaches for the treatment of cancer. As part of this effort, Dr Saif has worked as the principal investigator of multiple national and international studies investigating novel agents in the treatment of GI cancers. His research interest focuses on cancer pharmacology, pharmacogenetics, cancer drug development, and clinical investigations.

Dr Saif graduated from King Edward Medical University, Lahore, Pakistan. He completed his internal medicine residency at the University of Connecticut School of Medicine in Farmington, and a medical oncology fellowship at the National Cancer Institute, NIH, in Bethesda, Maryland, and the National Naval Medical Center, Bethesda. Dr Saif also completed a hematology fellowship at the National Heart, Lung, and Blood Institute (NHLBI), NIH, in Bethesda. After the clinical fellowship, he became a junior investigator in the Investigational Drug Branch, NCI, where he worked in the Gastrointestinal Malignancies Section.

Dr Saif is a member of the American Society of Clinical Oncology, American Society for Pharmacology and Experimental Therapeutics, and many others. He has published over 450 peer-reviewed articles about cancer treatment and research, over 80 abstracts and 20 book chapters, and serves on the editorial board of over 20 peer-reviewed cancer journals.

Personalizing Treatment: A Strategy to Improve Outcomes for Patients with mCRC

Jeffrey Weber, MD, PhD

Senior Member Moffitt Cancer Center

Director, Donald A Adam Comprehensive Melanoma Center

Dr. Weber earned his Ph.D. in molecular cell biology from Rockefeller University, and received his M.D. from New York University. He completed his internship and residency in Medicine at the University of California, San Diego, and his fellowship in Medical Oncology at the National Cancer Institute in Bethesda, MD.

His experience includes clinical, research and teaching positions at the University of California, Irvine, and the University of Southern California where he was Chief of Medical Oncology and Associate Director for Clinical Research at the USC/Norris Comprehensive Cancer Center. Dr. Weber is currently Director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center & Research Institute.

A specialist in cancer immunotherapy, Dr. Weber is principal investigator (PI) on several ongoing studies funded by the National Cancer Institute (NCI), including trials in clinical drug development, vaccines, and studies on autoimmunity and melanoma. He has been continuously NCI R01 funded for the last 16 years. Dr. Weber is also the Principal Investigator and Director of the Moffitt Skin Cancer SPORE (P50) NCI grant, a collaborative, multi-project translational research program. Dr. Weber has published more than 100 articles in the top peer-reviewed journals in his field. Dr. Weber currently sits on the scientific advisory boards of cancer-related biotechnology companies, numerous cancer institutions and foundations.

Dr. Weber’s research interests are in the field of immunotherapy for cancer. As a translational clinical investigator, Dr. Weber has performed a variety of vaccine trials, protocols involving adoptive cell therapy, and novel immunotherapy trials in melanoma patients. Clinically, he has held 10 investigator-initiated IND over the last decade, and has pursued cutting edge trials. He has been a pioneer in the clinical advancement of antibodies that induce autoimmunity as a surrogate for clinical benefit in cancer, and the management of the autoimmune side effects.

A Team-Based Approach to Optimizing Outcomes in Melanoma: Managing Immune Response-Related and Dermatologic Side Effects in Patients being Treated with Novel Therapies

Combining Emerging Immunotherapies and Targeted Agents for the Treatment of Melanoma

Kenneth Anderson, MD

Kraft Family Professor of Medicine

Harvard Medical School

Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at John’s Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome. He is the recipient of many scientific and humanitarian awards including the International Myeloma Workshop Waldenstrom’s Award in 2003, the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award in 2005, the American Association for Cancer Research Joseph H. Burchenal Award in 2007, and the American Society of Hematology William Dameshek Prize in 2008. He was elected into the Johns Hopkins Society of Scholars in 2009, the Institute of Medicine of the National Academy of Sciences in 2010, and the Royal College of Physicians and of Pathologists (UK) in 2010. In 2011 he received the American Society of Clinical Oncology David A. Karnofsky Award and the Hope Funds for Cancer Research Award of Excellence in Clinical Research, and in 2012 received the Ron Burton Humanitarian Award, the Harvard Medical School Warren Alpert Foundation Prize, and the American Cancer Society Medal of Honor.

Understanding the Fundamentals: Clonal Heterogeneity of Multiple Myeloma, Implications for Treatment of Relapsed/refractory Disease

The Evolving Landscape of Treatment Options for Relapsed/Refractory MM

Mark Socinski, MD

Professor of Medicine and Cardiothoracic Surgery

University of Pittsburgh Cancer Institute

Mark A. Socinski, MD, is a professor of medicine and cardiothoracic surgery at the University of Pittsburgh School of Medicine, and serves as director of the Lung Cancer Section at the University of Pittsburgh Cancer Institute, clinical associate director of the Lung SPORE, and co-director of UPMC Lung Cancer Center of Excellence, and co-director of the Lung and Thoracic Malignancies Program. Dr. Socinski specializes in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. Dr. Socinski is board-certified in internal medicine and medical oncology. He received an undergraduate degree and a medical degree at the University of Vermont in Burlington, VT. He completed a residency in internal medicine at Harvard Medical School in Boston and a fellowship in medical oncology at Dana-Farber Cancer Institute in Boston. Dr. Socinski holds memberships in numerous professional societies such as the American College of Physicians, American Society of Clinical Oncology, International Association for the Study of Lung Cancer, and the American College of Chest Physicians. Dr. Socinski serves as co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. Dr. Socinski’s primary research interests reside in all aspects of clinical trials related to the thoracic oncology population. He also serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative group trials.

Testing for Genetic Mutations in Advanced NSCLC

Clinical Challenges in the Personalized Treatment of Advanced NSCLC

Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

Deputy Head, Division of Internal Medicine

The University of Texas MD Anderson Cancer Center

Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA is the Frances King Black Endowed Professor and Deputy Head-Research in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center. He is also an adjunct professor at Baylor College of Medicine and University of Houston College of Pharmacy in Houston Texas. He received his medical degree Summa Cum Laude from the National and Kapodistrian University of Athens in Greece. Dr. Kontoyiannis also completed a post-doctoral clinical research fellowship at the Section of Infectious Diseases at The University of Texas MD Anderson Cancer Center in Houston, TX, followed by training in Internal Medicine at Baylor College of Medicine in Houston, TX, where he served as a Chief Medical Resident. He was subsequently trained as a clinical fellow in Infectious Diseases at Massachusetts General Hospital and obtained a Master in Clinical Sciences from Harvard Medical School in Boston. He spent 3 years at the Whitehead Institute for Biomedical Sciences/Massachusetts Institute of Technology as a fellow in the Harvard MIT Clinical Investigators Training Program. Dr. Kontoyiannis has authored more than 450 peer-reviewed manuscripts and been invited to give over 150 lectures in international conferences and prestigious institutions in US and abroad. He serves as an associate editor for Mycoses and J of Infection and sits in the editorial Boards of Antimicrobial Agents & Chemotherapy, JID. Transplantation Infectious Diseases and he is a reviewer for several other peer-reviewed journals in Infectious Diseases ,Oncology and Hematology. An international expert in clinical and experimental mycology, and the top three most highly cited investigators in the area of mycology with over 450 peer reviwed manuscripts and over 27000 citations. He is a fellow of the American College of Physicians and the Infectious Diseases Society of America. He is the recipient of many awards such as the 2004 American Society for Microbiology award for Outstanding Research in the Pathogenesis of Microbial Diseases (mentor), the America's Top Physicians in from Consumer’s Research Council of America and The University of Texas MD Anderson Cancer Center 2004 Faculty E. N Cobb Scholar Award, Faculty Achievement Award, M. D. Anderson Cancer Center, 2007, The Distinguished Clinical Faculty Mentoring Award of at MD Anderson Cancer Center, 2012, The Billy Cooper Memorial award from The Medical Mycology Society of Americas (2013), America’s Top doctors (2015), The Drouhet Medal from the European Confederation of Medical Mycology (2015). He is the president elect of Immunocompromised Host Society (2016-2018).

The War Against Invasive Mycoses: Critical Thinking in High-Risk Patients

The War Against Invasive Mycoses: A Case-Based Approach

Thomas Patterson, MD

Division Head and Division Chief, Infectious Diseases

University of Texas School of Medicine

Watch Connect online with thousands of your peers.
Connect Engage in real-time Q&A with top factuly.
Choose Learn about the latest treatment options.
Connect Earn AMA PRA
Category 1 Credits